Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Combination therapy for CLL in the CAPTIVATE trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.18
Views: 351

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Dr Ghia speaks with ecancer at EHA 23 about the design and early findings of the phase II CAPTIVATE study, treating CLL patients with ibrutinib and venetoclax.

He describes the sequencing of the two drugs, which are both approved as monotherapy, and assessments in place for depth of response.

Dr Ghia summarises some preliminary data, which indicate a good rate of response, and outlines when further results will be available.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence